Accès gratuit
Numéro
Med Sci (Paris)
Volume 19, Numéro 11, Novembre 2003
Page(s) 1093 - 1100
Section M/S Revues
DOI https://doi.org/10.1051/medsci/200319111093
Publié en ligne 15 novembre 2003
  1. Bascands JL, Girolami JP. La bradykinine. Med Sci 1996; 12: 582–92.
  2. Marceau F, Hess F, Bachvarov DR. The B1 receptor for kinins. Pharmacol Rev 1998; 50: 357–86.
  3. Schanstra JP, Bataille E, Marin Castano EM, et al. The B1 agonist [des- Arg10]-kallidin activates transcription factor NFkappaB and induces homologous upregulation of the B1-kinin receptor in cultured human lung fibroblasts. J Clin Invest 1998; 101: 2080–91.
  4. Harris B, Ju H, Venema V, et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001; 276: 16587–91.
  5. Duchene J, Schanstra JP, Pecher C, et al. A novel interaction between a Gprotein- coupled receptor and the phosphatase SHP-2 is involved in bradykinininduced inhibition of cell proliferation. J Biol Chem 2002; 277: 40375–83.
  6. AbdAlla S, Lother H, El Massiery A, Quitterer U. Increased AT1 heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7: 1003–9.
  7. Patel KV, Schrey MP. Inhibition of DNA synthesis and growth in human breast stroma cell by bradykinin: evidence for independent roles of B1 and B2 receptors in the respective control of cell growth and phospholipid hydrolyis. Cancer Res 1992; 52: 334–40.
  8. Dixon BS, Dennis MJ. Regulation of mitogenesis by kinins in arterial smooth muscle cells. Am J Physiol 1997; 273: C7–20.
  9. Tsuchida S, Miyazaki Y, Matsusaka T, et al. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature. Kidney Int 1999; 56: 509–16.
  10. Alric C, Pecher C, Cellier E, et al. Inhibition of IGF-Iinduced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int 2002; 62: 412–21.
  11. Graness A, Hanke S, Boehmer FD, et al. Proteintyrosine- phosphatasemediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogenactivated protein kinase by bradykinin in A431 cells. Biochem J 2000; 347: 441–7.
  12. Ricupero DA, Romero JR, Rishikof DG, Goldstein RH. Des-Arg10-kallidin engagement of B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. J Biol Chem 2000; 275: 12475–80.
  13. Gallagher AM, Yu H, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 1998; 32: 84–8.
  14. Wollert KC, Studer R, Doerfer K, et al. Differential effect of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 1997; 95: 1910–17.
  15. Silva JA, Araujo RC, Baltatu O, et al. Reduced cardiovascular hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 2000; 14: 1858–60.
  16. Schanstra JP, Neau E, Drogoz P, et al. In vivo bradykinin receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371–9.
  17. Sylvestre JB, Bergaya S, Tamarat R, et al. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678–83.
  18. Emanueli C, Salis MB, Stacca T, et al. Targeting B1 receptor for therapeutic neovascularisation. Circulation 2002; 105: 360–6.
  19. Volpert OA, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slow the growth of experimental tumors in rat. J Clin Invest 1996; 98: 671–9.
  20. Meneton P, Bloch-Faure M, Hagege A, et al. Tissue kallikrein is required for normal cardiac function in the mouse. Proc Natl Acad Sci USA 2001; 98: 2634–9.
  21. Pinto YS, Bader M, Pesquero JB, et al. Increased kallikrein excretion protects against cardiac ischemia. FASEB J 2000; 14: 1861–3.
  22. Yang XP, Liu YH, Scicli AG, et al. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knock out mice and kininogendeficient rats. Hypertension 1997; 30: 735–40.
  23. Brull D, Dhamrait S, Myerson S, et al. Bradykinin B2 BKR receptor polymorphism and leftventricular growth response. Lancet 2001; 358: 1155–6.
  24. Linz W, Wiemer G, Golke P, et al. Contributions of kinins to the cardiovascular effect of angiotensin converting enzyme inhibitor. Pharmacol Rev 1995; 47: 25–49.
  25. Pesquero JB, Araujo RC, Heppenstall PA, et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 2000; 97: 8140–5.
  26. Nakhostine N, Ribuot C, Lamontagne D, et al. Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol 1993; 110: 71–6.
  27. Marin Castano ECM, Schanstra JP, Neau E, et al. Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensinconverting enzyme inhibitor treatment. Circulation 2002; 105: 627–32.
  28. Witherow FN, Helmy A, Webb DJ, et al. Bradykinin contributes to the vasodilator effects of chronic angiotensinconverting enzyme inhibition in patients with heart failure. Circulation 2001; 104: 2177–81.
  29. Bralet J, Schwartz JC. Vasopeptidase inhibitors: An emerging class of cardiovascular drugs. Trends Pharmacol Sci 2001; 22: 106–9.
  30. Mukae S, Aoki S, Itoh S, et al. Bradykinin B(2) receptor gene polymorphism is associated with angiotensinconverting enzyme inhibitor related cough. Hypertension 2000; 36: 127–31.
  31. Marre M, Jeunemaitre X, Gallois Y, et al. Contribution of genetic polymorphism in the reninangiotensin system to the development of renal complications in insulindependent diabetes: Génétique de la Néphropathie Diabétique (GENEDIAB) study group. J Clin Invest 1997; 99: 385–95.
  32. Sharma K, Eltayeb BO, Mc Gowan TA, et al. Captoprilinduced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulindependent diabetic patients. Am J Kidney Dis 1999; 34: 819–23.
  33. Henriksen EJ, Jacob S, Augustin HJ, Dietze GJ. Glucose transport activity in insulin-resistant rat muscle. Effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes 2000; 45: S125–8.
  34. Haring HU, Tippmer S, Kellerer M, et al. Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor. Diabetes 1996; 45: S115–9.
  35. Carvalho CRO, Thirone ACP, Gontjo JAR, et al. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 1997; 46: 1950–7.
  36. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957–72.
  37. Cellier E, Mage M, Duchêne J, et al. Bradykinin reduces growth factor-induced glomerular Erk 1/2 phosphorylation. Am J Physiol 2003; 284: F282–92.
  38. Huang W, Gallois Y, Bouby N, et al. Genetically increased angiotensin Iconverting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98: 13330–4.
  39. Munzel T, Keaney JF. Are ACE Inhibitors a «Magic Bullet» against oxydative stress ? Circulation 2001; 104: 1571–4.
  40. Cloutier F, Couture R. Pharmacological characterization of the cardiovascular responses elicited by kinin B1 and B2 receptor agonists in the spinal cord of streptozotocin-diabetic rats. Br J Pharmacol 2000; 130: 375–85.
  41. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2002; 429: 161–76.
  42. De Sousa Buck HS, Ongali B, Thibault G, et al. Autoradiographic detection of kinin receptors in the human medulla of control, hypertensive, and diabetic donors. Can J Physiol Pharmacol 2002; 80: 249–57.
  43. Cloutier F, De Sousa Buck HS, Ongali B, Couture R. Pharmacologic and autoradiographic evidence for an up-regulation of kinin B2 receptors in the spinal cord of spontaneously hypertensive rats. Br J Pharmacol 2002; 135: 1641–54.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.